Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8299347 | 0.74 | TRPV4 (0.41) | ALDH1A1VCAM1CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL9723274 | 0.74 | AR (0.40) | KCNJ1 | |
| SCHEMBL9723151 | 0.73 | AR (0.37) | KCNJ1 | |
| SCHEMBL16428424 | 0.73 | TRPV4 (0.35) | KCNJ1 | |
| SCHEMBL29212552 | 0.73 | TRPV4 (0.32) | ALDH1A1KCNJ1 | |
| SCHEMBL6646922 | 0.71 | TRPV4 (0.36) | ALDH1A1 | |
| SCHEMBL22009905 | 0.70 | VCAM1 (0.51) | ALDH1A1VCAM1CYP1A2POLBMAPT | |
| SCHEMBL9723171 | 0.70 | TYR (0.41) | ALDH1A1CYP3A4MAPT | |
| SCHEMBL24108203 | 0.70 | CYP11B1 (0.37) | ALDH1A1 | |
| SCHEMBL20607571 | 0.70 | CYP11B1 (0.37) | CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119073-B2 | Peptides and their use as inhibitors of hepatitis C virus ns3 protease | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2006-10-10 | — | — | US | disclosed |
| US-20040142876-A1 | Peptides and their use as inhibitors of hepatitis c virus ns3 protease | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2004-07-22 | — | — | US | disclosed |
| EP-1392721-A1 | PEPTIDES AND THEIR USE AS INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002079234-A1 | PEPTIDES AND THEIR USE AS INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142876-A1 | Peptides and their use as inhibitors of hepatitis c virus ns3 protease | CTRL, VIP, CTSC | ALDH1A1 2261/4885VCAM1 2273/4885CYP3A4 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.